T Cell Sciences, Novartis Pharma AG deal

Novartis obtained options to license TCEL's TP10 soluble complement receptor 1 (SCR-1) and the gene for SCR-1 for xenotransplantation and allotransplantation. Under the two-year agreement, Novartis could license TP10 exclusively for transplant with worldwide marketing rights, except Japan. TCEL will receive annual option fees and supplies of TP10 from Novartis for development in other indications, a combination TCEL valued at $5 million. ...